Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $769.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price objective hoisted by Morgan Stanley from $768.00 to $769.00 in a research report sent to investors on Monday morning,Benzinga reports. The brokerage currently has an equal weight rating on the biopharmaceutical company’s stock.

A number of other equities analysts also recently commented on the stock. Wall Street Zen downgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, January 31st. HSBC started coverage on Regeneron Pharmaceuticals in a research note on Monday, November 24th. They set a “buy” rating and a $255.00 price target for the company. Hsbc Global Res upgraded Regeneron Pharmaceuticals to a “strong-buy” rating in a research note on Monday, November 24th. Bank of America raised shares of Regeneron Pharmaceuticals from an “underperform” rating to a “buy” rating and increased their target price for the company from $627.00 to $860.00 in a report on Wednesday, January 7th. Finally, Cantor Fitzgerald boosted their price objective on shares of Regeneron Pharmaceuticals from $740.00 to $800.00 and gave the stock an “overweight” rating in a research report on Monday. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $788.57.

Regeneron Pharmaceuticals Stock Up 2.1%

Shares of REGN opened at $775.28 on Monday. The company’s 50-day moving average price is $757.52 and its 200 day moving average price is $655.10. The firm has a market cap of $81.48 billion, a P/E ratio of 18.65, a price-to-earnings-growth ratio of 2.05 and a beta of 0.40. Regeneron Pharmaceuticals has a 12-month low of $476.49 and a 12-month high of $821.11. The company has a current ratio of 4.77, a quick ratio of 4.22 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share for the quarter, beating analysts’ consensus estimates of $10.74 by $0.70. The business had revenue of $3.88 billion during the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The company’s revenue was up 2.5% on a year-over-year basis. During the same period in the previous year, the firm posted $12.07 earnings per share. On average, sell-side analysts forecast that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 5th. Shareholders of record on Friday, February 20th will be paid a dividend of $0.94 per share. The ex-dividend date is Friday, February 20th. This is an increase from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. This represents a $3.76 annualized dividend and a yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is currently 8.47%.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, VP Jason Pitofsky sold 431 shares of the company’s stock in a transaction that occurred on Friday, November 7th. The stock was sold at an average price of $651.43, for a total transaction of $280,766.33. Following the completion of the transaction, the vice president directly owned 4,233 shares of the company’s stock, valued at approximately $2,757,503.19. This represents a 9.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Bonnie L. Bassler sold 1,500 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the completion of the sale, the director owned 1,703 shares in the company, valued at approximately $1,362,400. This represents a 46.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 7.02% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 0.3% during the fourth quarter. Vanguard Group Inc. now owns 9,075,153 shares of the biopharmaceutical company’s stock worth $7,004,838,000 after acquiring an additional 26,884 shares in the last quarter. State Street Corp increased its position in Regeneron Pharmaceuticals by 0.9% in the 2nd quarter. State Street Corp now owns 4,832,002 shares of the biopharmaceutical company’s stock worth $2,536,801,000 after buying an additional 42,343 shares during the period. Dodge & Cox grew its position in Regeneron Pharmaceuticals by 18.9% in the 3rd quarter. Dodge & Cox now owns 4,550,845 shares of the biopharmaceutical company’s stock worth $2,558,804,000 after purchasing an additional 724,562 shares during the last quarter. Franklin Resources Inc. increased its stake in Regeneron Pharmaceuticals by 6.0% during the third quarter. Franklin Resources Inc. now owns 2,453,143 shares of the biopharmaceutical company’s stock valued at $1,379,329,000 after acquiring an additional 139,647 shares during the period. Finally, Capital World Investors lifted its position in Regeneron Pharmaceuticals by 1.6% in the third quarter. Capital World Investors now owns 1,998,366 shares of the biopharmaceutical company’s stock worth $1,123,609,000 after purchasing an additional 32,348 shares during the period. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.